Cancer immunotherapy comes of age

By I. Mellman, George Coukos, G. Dranoff. Nature, 2011

3,898 citations recorded by the source corpus.

Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/5d566c4865ff5479009c61ff151972af896ce955

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

In Oncology

Citations in the corpus

Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses (2015, background): “This includes the accumulation of immunoregulatory cells such as regulatory CD4+ T cells (Tregs), myeloid derived suppressor cells (MDSCs) and tolerogenic antigen-presenting cells (APCs) (Mellman et al., 2011; Shiao et al., 2011).”
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (2012, neutral): “All patients All doses 49 5 10 (3-22) 6 12 (5-25) 31 (17-45)”
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab (2023, background): “These include dysfunctional T-cell signaling,(3) suppressive regulatory cells,(4) and key “immune checkpoints” that regulate the outcome of lymphocyte engagement with antigen-presenting cells and tumor cells.(5,6) In JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 32 NUMBER 10 APRIL ”
Oncology meets immunology: the cancer-immunity cycle. (2013, background): “…T regulatory cell responses rather than effector responses, T cells may not properly home to tumors, may be inhibited from infiltrating the tumor, or (most importantly) factors in the tumor microenvironment might suppress those effector cells that are produced (reviewed by Motz and Coukos, 2013).”
HIF Transcription Factors, Inflammation, and Immunity (2014, background): “As a result, new rational therapeutic combinations targeting hypoxia and angiogenesis (Rapisarda and Melillo, 2012) or novel immunotherapies (Mellman et al., 2011) could help to overcome the multiple mechanisms of tumor resistance.”